Aclaris Therapeutics (NASDAQ:ACRS) dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate-to-severe atopic dermatitis
ATI-1777 is a topical Janus kinase (JAK) 1/3 inhibitor designed to provide JAK inhibition at the site of application and be rapidly metabolized in the systemic circulation.
The trial will enroll some 42 subjects who will apply ATI-1777 or vehicle twice daily for 28 days. The study’s primary endpoint is the percentage change from baseline in the eczema area and severity index score at week 4.
“This trial is an important first step in the clinical development of ATI-1777 and we hope to establish that a topical JAK inhibitor can safely and effectively treat atopic dermatitis while limiting systemic exposure,” Dr. David Gordon, Aclaris’ CMO, said in a statement.
